genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2021
Juno Therapeutics
Cancer
Celularity: Productizing Placental-Derived Stem Cells for Any Patient
Cancer
Celgene to Acquire Juno for $9B, Expanding CAR-T, TCR Presence
A-Lists
10 Takeover Targets for 2017
Cancer
Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
A-Lists
Unlucky 13: Top Clinical Trial Failures of 2016
Industry News
Juno Licenses BCMA from MSK, Eureka Therapeutics
Insights
Patient Deaths Unlikely to Derail Cancer Therapies
Industry News
Juno Buys RedoxTherapies for $10M+
Industry News
Juno Seeks Trial Protocol Change Following Patient Deaths
A-Lists
Nine Takeover Targets of 2015
1
2
Page 1 of 2
Scroll Up
Scroll Up
